BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10822991)

  • 1. The role of methylation in CML.
    Rachmilewitz EA
    Przegl Lek; 2000; 57 Suppl 1():25-6. PubMed ID: 10822991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.
    Asimakopoulos FA; Shteper PJ; Krichevsky S; Fibach E; Polliack A; Rachmilewitz E; Ben-Neriah Y; Ben-Yehuda D
    Blood; 1999 Oct; 94(7):2452-60. PubMed ID: 10498618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
    Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
    Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
    Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.
    Gupta M; Milani L; Hermansson M; Simonsson B; Markevärn B; Syvänen AC; Barbany G
    Biochem Biophys Res Commun; 2008 Feb; 366(3):848-51. PubMed ID: 18082628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation status of RASSF1A in patients with chronic myeloid leukemia.
    Avramouli A; Tsochas S; Mandala E; Katodritou E; Ioannou M; Ritis K; Speletas M
    Leuk Res; 2009 Aug; 33(8):1130-2. PubMed ID: 19193434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of PRAME gene in chronic myeloid leukemia.
    Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; Jose-Eneriz ES; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
    Leuk Res; 2007 Nov; 31(11):1521-8. PubMed ID: 17382387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
    Campanini F; Santucci MA; Pattachini L; Brusa G; Piccioli M; Barbieri E; Babini L; Tura S
    Haematologica; 2001 Feb; 86(2):167-73. PubMed ID: 11224486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.
    Reid AG; Tarpey PS; Nacheva EP
    Genes Chromosomes Cancer; 2003 Jul; 37(3):282-90. PubMed ID: 12759926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
    Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
    Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia.
    Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; San Jose-Eneriz E; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
    Leuk Res; 2008 Mar; 32(3):487-90. PubMed ID: 17765966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3.
    Yang MY; Chang JG; Lin PM; Tang KP; Chen YH; Lin HY; Liu TC; Hsiao HH; Liu YC; Lin SF
    Cancer Sci; 2006 Dec; 97(12):1298-307. PubMed ID: 16999817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia, BCR-ABL1+.
    Vardiman JW
    Am J Clin Pathol; 2009 Aug; 132(2):250-60. PubMed ID: 19605820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
    Shteper PJ; Siegfried Z; Asimakopoulos FA; Palumbo GA; Rachmilewitz EA; Ben-Neriah Y; Ben-Yehuda D
    Leukemia; 2001 Apr; 15(4):575-82. PubMed ID: 11368359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
    Amin HM; Hoshino K; Yang H; Lin Q; Lai R; Garcia-Manero G
    J Pathol; 2007 Aug; 212(4):402-10. PubMed ID: 17503411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.